targeted therapy Archives - Drugs in Context

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors

Darren MC Poon, Kuen Chan, Angus Kwong-Chuen Leung, Brian Ng, Foon-Yiu Cheung, Steven Wai-Kwan Siu, Hong Kong Society of Uro-Oncology

Article Type

Original Research

Published

21 Jun 2023

In this study, the authors investigated the toxicity and efficacy of cabozantinib in Chinese patients who progressed on VEGFR TKIs and/or ICIs in real-life clinical practice.

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks

Andrea De Giglio, Biagio Ricciuti, Giulio Metro

Article Type

Editorial

Published

02 May 2023

This Editorial by De Giglio, Ricciuti and Metro introduces the series Treatment of advanced non-small-cell lung cancer: one size does not fit all.

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma

Francesco Serra, Carlotta Faverio, Angioletta Lasagna, Stefania Barruscotti, Tommaso Dominioni, Marco Benazzo, Paolo Pedrazzoli, Silvia Chiellino

Article Type

Review

Published

09 Aug 2021

The aim of this review is to investigate the role of treatment beyond progression and locoregional approaches in BRAF-mutated metastatic melanoma and provide oncologists dealing with this malignancy a useful road map on when and why to choose this strategy.

Onset of vitiligo following targeted therapy for BRAFV600E-mutated melanoma: case report

Sonia Brugnara MD, Mariacristina Sicher MD, Elena Maria Bonandini MD, Mattia Barbareschi MD, Carlo Renè Girardelli MD, Orazio Caffo MD

Article Type

Case Report

Published

18 Dec 2019

This case study covers a patient who received dabrafenib and trametinib and developed vitiligo-like depigmentation after treatment cessation.

Drug therapy for double-hit lymphoma

Vania Phuoc MD, Jose Sandoval-Sus MD, Julio C Chavez MD, MS

Article Type

Review

Published

02 Dec 2019

This review discusses the role of hematopoietic stem cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell therapy in DHL, as well as the role of potential novel agents such as BCL2 inhibitors, checkpoint inhibitors, bromodomain and extraterminal (BET) family inhibitors, Pi3K inhibitors, and others.